Related Experiment Videos
[Second allogeneic transplant for leukemia relapsed after first allogeneic transplantation]
Dong-lin Yang1, Ming-zhe Han, Si-zhou Feng
1Institute of Hematology and Blood Diseases Hospital, CAMS and PUMC, Tianjin 300020, China.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi
|June 9, 2004
Summary
Second allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers a therapeutic option for leukemia relapse post-initial allo-HSCT. While associated with significant risks, it provides a chance for long-term survival in select patients.
Area of Science:
- Hematology
- Oncology
- Transplantation Medicine
Context:
- Leukemia relapse after first allogeneic hematopoietic stem cell transplantation (allo-HSCT) presents a critical challenge in hematologic oncology.
- Limited therapeutic options exist for patients experiencing secondary relapse following an initial allo-HSCT.
- Second allo-HSCT is being explored as a potential salvage strategy.
Purpose:
- To evaluate the efficacy and outcomes of second allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with relapsed leukemia after a first allo-HSCT.
- To assess engraftment, graft-versus-host disease (GVHD), and survival rates in this high-risk patient population.
Summary:
- Ten patients with relapsed leukemia (5 AML, 4 ALL, 1 CML) underwent second allo-HSCT.
- Engraftment was achieved in all evaluable cases, with a median time of 11 days for neutrophil recovery and 12 days for platelet recovery.
- The 2-year leukemia-free survival was 20%, with a transplantation-related mortality of 50% and a relapse rate of 30%.
Impact:
- Second allo-HSCT can lead to long-term leukemia-free survival in a subset of patients with relapsed leukemia.
- This procedure carries substantial risks, including GVHD, infections, and treatment-related mortality, necessitating careful patient selection.
- The findings suggest that second allo-HSCT is a viable therapeutic alternative for carefully selected individuals facing leukemia recurrence after initial stem cell transplantation.